.jpeg)
{{ variable.name }}
Introduction to filgotinib
Generic name: filgotinib
Trade name: Jyseleca
Full names: Jyseleca, filgotinib, filgotinib
Indications:
For the treatment of adult patients with moderate to severe rheumatoid arthritis (RA) who have an inadequate response to or intolerance to one or more disease-modifying antirheumatic drugs (DMARDs). In terms of medication, Jyseleca can be used as monotherapy or in combination with methotrexate (MTX).
Usage and Dosage:
The usual dose for adults is 200 mg of filgotinib taken orally once daily. In addition, depending on the patient's condition, 100 mg can be taken daily. Follow your doctor's advice carefully.
If you are over 75 or have kidney problems, your doctor may recommend taking 100 mg daily. Filgotinib is not recommended if you have severe liver problems (consult your doctor).
Do not break, crush, or chew the tablets; take them with or between meals.
Specifications:
100mg, 200mg tablets
Adverse reactions:
Common adverse reactions: nausea, upper respiratory tract infection, urinary tract infection and dizziness
Under clinical study Adverse reactions that occurred: urinary tract infection, upper respiratory tract infection, herpes zoster, pneumonia, neutropenia, hypercholesterolemia, dizziness, nausea, increased blood creatine phosphokinase
Contraindications:
Those allergic to any component of this product.
Active tuberculosis (TB) or active severe infection.
Pregnant.
Precautions:
Infection: If you develop fever or chills, shortness of breath, persistent cough, or fatigue, you need to inform your doctor promptly. Jyseleca can reduce the body's ability to fight infection. It may worsen existing infections or increase the risk of new infections. Patients aged 75 and older are at higher risk of infection.
Tuberculosis: If you have previously had tuberculosis or have been exposed to someone with tuberculosis, you may need to be tested for tuberculosis before and during treatment with Jyseleca.
Herpes zoster: Jyseleca can cause shingles to come back. Tell your doctor if you develop painful rashes and blisters during treatment with Jyseleca; these may be signs of shingles.
Hepatitis: Tell your doctor if you have ever had hepatitis B or C.
Cancer: If you have cancer, your doctor will decide whether you can be treated with Jyseleca.
Skin cancer: If you are at high risk for skin cancer, your doctor may take preventive measures, such as regular skin exams, while you are being treated with Jyseleca. Tell your doctor right away if you have: new marks or any changes in an area of your skin. Some patients treated with Jyseleca have developed skin cancer.
Pregnancy: Jyseleca may reduce fertility or cause infertility in male patients.
Vaccines: Certain types of vaccines are not recommended during treatment with Jyseleca. If you have recently been vaccinated or plan to receive a vaccine, talk to your doctor before starting treatment with Jyseleca.
Other conditions: If you have heart disease, high blood pressure, or high cholesterol, tell your doctor before treatment with Jyseleca.
Thrombi: If you have had leg vein or lung blood clots before, please inform your doctor promptly if you experience leg swelling and pain, chest pain, or shortness of breath, as these may be signs of venous thrombosis.
Storage:
Keep in original packaging to prevent moisture.
Mechanism of action:
Filgotinib is a selective and reversible adenosine triphosphate (ATP) competitive inhibitor of Janus kinase (JAK). JAK is an intracellular enzyme that transmits signals resulting from cytokine or growth factor-receptor interactions to the cell membrane and affects cellular processes such as hematopoiesis, cytokine signaling, and immune cell function. In the signaling pathway, JAK phosphorylates and activates signal transducers and activators of transcription (STATs) that regulate intracellular activity, including gene expression. Filgothinib regulates signaling pathways by inhibiting STAT phosphorylation and activation.
Safety and efficacy:
The FINCH study included three phase III trials, all of which met their primary endpoints. Compared with placebo or MTX, filgotinib was able to achieve ACR20/50/70 response indicators well, and all individual ACR components showed improvement. The results showed that compared with placebo or MTX, filgotinib treatment consistently achieved ACR20/50/70 response indicators and improved on all ACR criteria. Compared with placebo or MTX at weeks 12 and 24, patients receiving 200 mg Patients treated with filgotinib in combination with MTX or other conventional synthetic antirheumatic drugs achieved lower disease activity and/or remission (DAS28-CRP ≤3.2 and DAS28-CRP The proportion of patients with <2.6) increased significantly. In patients with poor response to MTX, filgotinib + MTX compared with placebo + MTX at week 24 The combined use of MTX can significantly inhibit the progression of structural joint damage in patients.